ASX Announcement

Visioneering Makes First Entry into International Markets

Innovative multifocal contact lens establishes beach head account in Australia

Atlanta, Georgia, USA, September 4, 2018: Visioneering Technologies, Inc. (ASX: VTI) today announced its first customer agreement outside of the United States, with Sydney-based optometrist Oliver Woo, BOptom, FIAOMC.

A leading specialist in the management of paediatric myopia, Mr. Woo is on both the Executive and Fellowship committees of the International Academy of Orthokeratology and Myopia Control (IAOMC), a global professional organization for practitioners who are passionate about addressing paediatric myopia. He is also the first Orthokeratologist in Australia to obtain a fellowship from the International Academy of Orthokeratology. Mr. Woo shares his practical knowledge of myopia management globally, and in Asia in particular, through an extensive program of lectures and workshops.

“I’m thrilled to be the first Australian optometrist and the first eyecare professional outside the United States to offer this uniquely innovative and powerful suite of contact lens products for myopic progression control and presbyopia. The lenses have been shown to slow myopia progression in children, and to provide excellent near and distance vision in presbyopic adults,” Woo said. “I’m particularly excited to add Visioneering’s NaturalVue Multifocal 1 Day Contact Lenses to my options for nearsighted children.”

Progressive paediatric myopia affects a high percentage of children in industrialized nations. A study recently published in the peer-reviewed journal, *Eye & Contact Lens*, documented that VTI’s NaturalVue MF lens reduced myopia progression in children by approximately 96%, with 98.4% of the children in the study showing a decrease in the rate of worsening of their myopia.¹

“We are delighted to be commencing our entry into the Australian market with a recognised leader in the field of myopia progression like Mr. Woo,” said Visioneering’s CEO, Dr. Stephen Snowdy. “Following the receipt of our CE Mark earlier this year, we have been putting in place the logistics to market our products outside the United States. Oliver and his patients are the first outside the U.S. to enjoy the benefits of NaturalVue Multifocal contact lenses, and this agreement marks the beginning of the planned international expansion of VTI’s revolutionary NaturalVue Multifocal. We anticipate making further announcements of agreements over the coming weeks and months with leading optometrists and distribution partners as we implement our initial international market expansion.”

For more information, please contact:

<table>
<thead>
<tr>
<th>Company</th>
<th>Investor and media relations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Snowdy</td>
<td>Kyahn Williamson</td>
</tr>
<tr>
<td>CEO, Visioneering Technologies, Inc.</td>
<td>WE Buchan</td>
</tr>
<tr>
<td>Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a></td>
<td>Tel: +61 (3) 9866 4722</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:kwilliamson@buchanwe.com.au">kwilliamson@buchanwe.com.au</a></td>
</tr>
</tbody>
</table>

About Visioneering Technologies, Inc.
Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI’s Neurofocus Optics® technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and received the CE Mark, as well as TGA approval in early 2018. VTI recently commenced its US market expansion for NaturalVue MF contact lenses, and has broadened its reach into international markets in 2018. VTI also sells and plans additional contact lens products.

Foreign Ownership Restriction:
VTI’s CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of VTI’s CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements:
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as, our expectations with respect to our ability to develop and commercialize new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

MKT – VTI – ASX2